Klampenborg, Denmark

Soren Peter Olsen

This inventor holds 1 USPTO granted patent. Top assignee: Poseidon Pharmaceuticals A/s. Active years: 2004.


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Soren Peter Olsen: Innovator in Chemical Compounds for Immune Dysfunction

Introduction

Soren Peter Olsen is a notable inventor based in Klampenborg, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the development of chemical compounds aimed at treating immune dysfunction. His innovative work has the potential to impact many lives.

Latest Patents

Olsen holds a patent for "Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction." This invention relates to chemical compounds that exhibit inhibitory activity on an intermediate conductance Ca-activated potassium channel (IK). The compounds are designed for the treatment or alleviation of diseases or conditions associated with immune dysfunction.

Career Highlights

Olsen is currently associated with Poseidon Pharmaceuticals A/S, where he continues to advance his research and development efforts. His work in this company underscores his commitment to improving therapeutic options for patients suffering from immune-related conditions.

Collaborations

Olsen has collaborated with notable colleagues, including Bo Skaaning Jensen and Palle Christophersen. These partnerships have likely enhanced the scope and impact of his research endeavors.

Conclusion

Soren Peter Olsen's contributions to the field of pharmaceuticals, particularly through his patent on chemical compounds for immune dysfunction, highlight his role as an innovator. His work at Poseidon Pharmaceuticals A/S and collaborations with esteemed colleagues further emphasize his dedication to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…